

LITERATURE CITED

- Atkin, P. and R. Friedman. 2005. **Molecular Quantum Mechanics**. 4th ed. Oxford University Press, New York.
- Benjahad, A., K. Courte, J. Guillemont, D. Mabire, S. Coupa, A. Poncelet, I. Csoka, K. Andries, R. Pauwels, M.P. de Bethune, C. Monneret, E. Bisagni, C.H. Nguyen and D.S. Grierson. 2004. 4-Benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: Optimization and in vitro evaluation against clinically important HIV mutant strains. **Journal of Medicinal Chemistry**. 47(22): 5501-5514.
- Chan, J.H., G.A. Freeman, J.H. Tidwell, K.R. Romines, L.T. Schaller, J.R. Cowan, S.S. Gonzales, G.S. Lowell, C.W. Andrews, D.J. Reynolds, M.S. Clair, R.J. Ferris R.G. Hazen, K.L. Creech, G.B. Roberts, S.A. Short, K. Weaver, G.W. Koszalka, and L.R. Boone. 2004. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. **Journal of Medicinal Chemistry**. 47: 1175-1182.
- Cywin, C.L., J.M. Klunder, M.A. Hoermann, J.R. Brickwood, E. David, P.M. Grob, R. Schwartz, D. Pauletti, K.J. Barringer, C.K. Shih, C.L. Sorge, D.A. Erickson, D.P. Joseph and S.E. Hattox. 1998. Novel non-nucleoside Inhibitors of HIV-1 reverse transcriptase. 8. 8-aryloxymethyl- and 8-arylthiomethyl dipyridodiazepinones. **Journal of Medicinal Chemistry**. 41: 2972-2984.
- Dapprich, S., I. Komaromi, K.S. Byun, K. Morokuma and M.J. Frisch. 1999. A new ONIOM implementation in Gaussian98. part I. The calculation of energies, gradients, vibrational frequencies and electric field derivatives. **Journal of Molecular Structure (Theochem)**. 1-21: 461-462.
- Das, K., J. Ding, Y. Hsiou, A.D. Clark, H. Moereels, L. Koymans, K. Andries, R. Pauwels, P.A.J. Janssen, P.L. Boyer, P. Clark, R.H. Smith, M.B.K. Smith, C.J. Michejda S. H. Hughes and E. Arnold. 1996. Crystal structures of 8-Cl and 9-Cl TIBO

complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. **Journal of Molecular Biology.** 264: 1085–1100.

De Clercq, E. 1994. HIV resistance to reverse transcriptase inhibitors. **Biochemical Pharmacology.** 47: 155-169.

_____. 1995a. Antiviral therapy for human immunodeficiency virus infections. **Clinical Microbiology Reviews.** 8: 200-239.

_____. 1995b. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV-1 infections. **Journal Medicinal Chemistry.** 38: 2491-2517.

_____. 1998. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. **Antiviral Research.** 38: 15.-179.

_____. 1999. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. **IL Farmaco.** 54: 26–45.

_____. 2001. Antiviral drugs: current state of the art. **Journal of Clinical Virology.** 22: 73–89.

_____. 2002. Review: new developments in anti-HIV chemotherapy. **Biochimica et Biophysica Acta.** 1587: 258– 275.

_____. 2004. Review: Antiviral drugs in current clinical use. **Journal of Clinical Virology.** 30: 115–133.

El-Brollosy, N. R., P.T. Jorgensen, B. Dahan, A.M. Boel, E.B. Pedersen and C. Nielsen. 2002. Synthesis of novel N-1 (Allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity

against HIV-1 and its mutants. **Journal of Medicinal Chemistry**. 45(26): 5721-5726.

Esnouf, R., J. Ren, C. Ross, Y. Jones, D. Stammers and D. Stuart. 1995. Mechanism of inhibition of HIV-1 RT by non-nucleoside inhibitors. **Nature Structure Biology**. 2: 303-308.

Frisch, M.J., G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, J.A. Montgomery, T. Vreven, K.N. Kudin, J.C. Burant, J.M. Millam, S.S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G.A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J.E. Knox, H.P. Hratchian, J.B. Cross, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, P.Y. Ayala, K. Morokuma, G.A. Voth, P. Salvador, J.J. Dannenberg, V.G. Zakrzewski, S. Dapprich, A.D. Daniels, M.C. Strain, O. Farkas, D.K. Malick, A.D. Rabuck, K. Raghavachari, J.B. Foresman, J.V. Ortiz, Q. Cui, A.G. Baboul, S. Clifford, J. Cioslowski, B.B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R.L. Martin, D.J. Fox, T. Keith, M.A. Al-Laham, C.Y. Peng, A. Nanayakkara, M. Challacombe, P.M.W. Gill, B. Johnson, W. Chen, M.W. Wong, C. Gonzalez, J.A. Pople. 2003. **Gaussian 03**, revision B.05; Gaussian, Inc.: Pittsburgh.

Giada, L., C. Giuseppe, C. Reynel, M. Elena, R. Anna, G. Sandra, H. Ulrich, S. Silvio and M. Giovanni. 2004. Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone non-nucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex. **Antimicrobial agents and chemotherapy**. 48(5): 1570-1580.

Giuseppe, C., R. Anna, M. Giovanni, N. Vito, F. Caterina, C. Bruno, M. Elena and N. Ettore. 2002. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. **Current pharmaceutical design**. 8(8): 615-657.

- Goff, P. 1990. Retroviral reverse transcriptase: Synthesis, structure and function. **Journal of Acquired Immune Deficiency Syndromes**. 3: 817-831.
- Hannongbua, S., K. Nivesanond, L. Lawtrakul, P. Pungpo and P. Wolschann. 2001. 3D-Quantitative Structure-Activity Relationships of HEPT Derivatives as HIV-1 Reverse Transcriptase Inhibitors, Based on *Ab Initio* Calculations. **Journal of Chemical Information and Modeling**. 41: 848-855.
- Hsiou, Y., J. Ding, K. Das, A.D. Clark, J.P. Kleim, M. Rosner, I. Winkler, G. Riess, S.H. Hughes and E. Arnold. 1998. Structures of Tyr188Leu mutant and wild-type HIV-1 RT complexed with the non-nucleoside inhibitors HBY 097: inhibitor flexibility is useful design feature for reducing drug resistance. **Journal of Molecular Biology**. 284: 313-323.
- Hsiou, Y., J. Ding, K. Das, A.D. Clark, P.L. Boyer, P. Lewi, P.A.J. Janssen, M. Rosner, S.H. Hughes and E. Arnold. 2001. The Lys103Asn Mutation of HIV-1 RT: A Novel mechanism of drug resistance. **Journal of Molecular Biology**. 309: 437-445.
- Jacobo-Molina, A. and E. Arnold. 1991. HIV reverse transcriptase structure function relationships. **Biochemistry**. 30: 6351-6361.
- Jacobo-Molina, A., J. Ding, R.G. Nanni, A.D. Clark, X. Lu, R.L. Tantillo, C. Williams, G. Kamer and A.L. Ferris. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 resolution show bent DNA. **Proceeding of the National Academy of Sciences of the United States of America**. 90: 6320-6324.
- Jonckbeere, H., J. Anné and E. De Clercq. 2000. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. **Medical Research and Reviews**. 20: 129-154.

- Karadakov, P.B. and K. Morokuma. 2000. ONIOM as an efficient tool for calculating NMR chemical shielding constants in large molecules. **Chemical Physics Letters**. 317: 589–596.
- Kristya, S., P. Pulay. 1994. Can (semi)local density functional theory account for the London dispersion forces? **Chemical Physics Letters**. 229: 175–180.
- Kuno, M., S. Hannongbua and K. Morokuma. 2003. Theoretical investigation on and HIV-1 reverse transcriptase binding site interaction, based on ONIOM method. **Chemical Physics Letters**. 380: 456–463.
- Lindberg, J., S. Sigurðsson, S. Lowgren, H.O. Andersson, C. Sahlberg, R. Noreen, H. Zhang and T. Unge. 2002. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. **European Journal of Biochemistry**. 269: 1670-1677.
- Mao, C., E.A. Sudbeck, T. K. Venkatachalam and F.M. Uckun. 2000. Structure- based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. **Biochemical Pharmacology**. 60(9): 1251-1265.
- Mei, Y., X. He, Y. Xiang, D.W. Zhang, J.Z.H. Zhang. 2005. Quantum Study of Mutational Effect in Binding of Efavirenz to HIV-1 RT. **PROTEINS: Structure, Function, and Bioinformatics**. 59: 489–495
- Morokuma K. 2002. New challenges in quantum chemistry: quests for accurate calculations for large molecular systems. **Philosophical Transactions of the Royal Society of London Series A**. 360: 1149–1164.
- Morokuma, K. 2003. ONIOM and its applications to material chemistry and catalyses. **Bulletin of the Korean Chemical Society**. 24(6): 797-801.

- Morokuma, K., Q. Wang and T. Vreven. 2006. Performance Evaluation of the Three-layer ONIOM method: Case study for a zwitterionic peptide. **Journal of chemical theory and computation.** 2(5): 1317-1324.
- Mulholland, A.J. 2005. Modelling enzyme reaction mechanisms, specificity and catalysis. **Drug discovery today.** 10: 1393-1402.
- Nunriam, P., M. Kuno, S. Saen-oon and S. Hannongbua. 2005. Particular interaction between efavirenz and HIV-1 reverse transcriptase binding site as explained by the ONIOM method. **Chemical Physics Letters.** 405: 198-202.
- Pata, J.D., W.G. Stirtan, S.W. Goldstein and T.A. Steitz. 2004. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. **Proceedings of the National Academy of Sciences of the United States of America.** 101 (29): 10548–10553.
- Ren, J., R. Esnouf, E. German, D. Somers, C. Ross, I. Kirby, J. Keeling, G. Darby, Y. Jones, D.I. Stuart and D. K. Stammers. 1995. High resolution structures of HIV-1 RT from four RT- inhibitor complexes. **Nature Structure Biology.** 2: 293-302.
- Ren, J., J. Milton, K.L. Weaver, S.A. Short, D.I. Stuart and D.K. Stammers. 2000. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. **Structure.** 8: 1089–1094.
- Ren, J., C. Nichols, L. Bird, P. Chamberlain, K. Weaver, S. Short, D.I. Stuart and D.K. Stammers. 2001. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. **Journal of Molecular Biology.** 312: 795-805.

- Ren, J., C.E. Nichol, P.P. Chamberlain, K.L. Weaver, S.A. Short and D.K. Stammers. 2004. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. **Journal of Molecular Biology**. 336: 569–578.
- Richman, D.D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S.A. Spector and J. Sullivan. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. **Journal of Virology**. 68: 1660–1666.
- Ridder, L and A.J. Mulholland. 2003. Modeling biotransformation reactions by combined quantum mechanical/molecular mechanical approaches: from structure to activity. **Current Topics Medicinal Chemistry**. 3: 1241-1256.
- Robert, K., K. Ronald, R. Carol and E.V. Susan. 2002. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. **Antimicrobial agents and chemotherapy**. 46(6): 1640-1646.
- Roey, V.P., J.M. Salerno, W.L. Duax, C.K. Chu, M.K. Ahn and R.F. Schinazi. 1988. Solid-state conformation of anti-human immunodeficiency virus type-1 agents; crystal structure of three 3'-azido-3'-deoxythymidine analogues. **Journal of the American Chemical Society**. 110: 2277-2282.
- Saen-Oon, S., S. Hannongbua and P. Wolschann. 2003. Structural flexibility of non-nucleoside HIV-1 reverse transcriptase inhibitor: 9-Cl TIBO as explained by potential energy surface and ^{13}C and ^1H NMR calculations, based on *ab initio* and density functional study. **Journal Chemical Information and Modeling**. 43: 1412-1422.
- Saen-oon, S. 2003. **Thesis**: Structural Conformational Analysis of 8-Cl and 9-Cl *TIBO* and Investigation on the HIV-1 RT/*TIBO*s Interactions, Based on Quantum Chemical Calculations. 205 pages.

- Saen-oon, S., M. Kuno and S. Hannongbua. 2005. Binding Energy Analysis for Wild-Type and Y181C Mutant HIV-1 RT/8-Cl *TIBO* Complex Structures: Quantum Chemical Calculations Based on the ONIOM Method. **PROTEINS: Structure, Function, and Bioinformatics**. 61: 859–869.
- Sardana, V.V., E.A. Emini, L. Gotlib, D.J. Graham, D.W. Lineberger, W.J. Long and J. A. Wolfgang. 1992. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. **Journal of Biology Chemistry**. 267: 17526–17530.
- Sarafianos, S.G., S.H. Hughes and E. Arnold. 2004. Review : Designing anti- AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs. **The International Journal of Biochemistry & Cell Biology**. 36: 1706–1715.
- Schinazi, R.F., B.A. Larder and J.W. Mellors. 1997. Mutations in retroviral genes associated with drug resistance. **International Antiviral News**. 5: 129-135.
- Smith, M.B.K., M.L Lamb, J. Tirado-Rives, W.L. Jorgensen, C.J. Michejda, S.K. Ruby and R.H. Smith, Jr. 2000. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity. **Protein Engineering**. 13(6): 413-421.
- Spence, R.A., W.M. Kati, K.S. Anderson and K.A. Johnson. 1995. Mechanism of inhibition of HIV-1 RT by non-nucleoside inhibitors. **Science**. 267: 988-993.
- Spence, R.A., K.S. Anderson and K.A. Johnson. 1996. HIV-1 RT to non-nucleoside inhibitors. **Biochemistry**. 35: 1054-1063.
- Svensson, M., S. Humbel, R.D.J. Froese, T. Matsubara, S. Sieber and K. Morokuma 1996. ONIOM: A multilayered integrated MO + MM method for geometry optimizations and single point energy predictions. A test for Diels-Alder

Reactions and $\text{Pt}(\text{P}(t\text{-Bu})_3)_2 + \text{H}_2$ oxidative addition. **Journal of Physical Chemistry**. 100: 19357-19363.

Tantillo, C., J. Ding, A. Jacobo-Molina, R.G. Nanni, P.L. Booyer, S.H. Hughes, R. Pauwels, K. Andries, P.A.J. Janssen and E. Arnold. 1994. Location of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. **Journal of Molecular Biology**. 243: 369-387.

Tsuzuki, S. and H.P. Luthi. 2001. Interaction energies of van der Waals and hydrogen bonded systems calculated using density functional theory: assessing the PW91 model. **Journal of Chemical Physics**. 114: 3949.

Udier-Blagovic, M., E.K. Watkins, J. Tirado-Rives and W.L. Jorgensen. 2003a. Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase. **Bioorganic & Medicinal Chemistry Letters**. 13: 3337-3340.

Udier-Blagovic, M., J. Tirado-Rives and W.L. Jorgensen. 2003b. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. **Journal of the American Chemical Society**. 125(20): 6016-6017.

Udier-Blagovic, M., J. Tirado-Rives and W.L. Jorgensen. 2004. Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues. **Journal of Medicinal Chemistry**. 47: 2389-2392.

Vreven, T., K. Morokuma, Ö. Farkas, H.B. Schlegel and M.J. Frisch. 2003. Geometry optimization with QM/MM, ONIOM and other combined methods. I. Microiterations and constraints. **Journal of Computational Chemistry**. 24: 760-769.

Wamberg, M., E.B. Pedersen, N.R. El-Brollosy and C. Nielsen. 2004. Synthesis of 6-arylvinyl analogues of the HIV drugs SJ-3366 and emivirine. **Bioorganic & Medicinal Chemistry**. 12(5): 1141-1149.

- Wang, D.P., R.C. Rizzo, J.T. Rives and W.L. Jorgensen. 2001a. Antiviral Drug Design: Computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. **Bioorganic & Medicinal Chemistry Letters**. 11: 2799–2802.
- Wang, J., P. Morin, W. Wang and P.A. Kollman. 2001b. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. **Journal of the American Chemical Society**. 123: 5221-5230.
- Warshel, A., M. Levitt. 1976. Theoretical Studies of Enzymic Reactions: Dielectric, Electrostatic and Steric Stabilization of the Carbonium Ion in the Reaction of Lysozyme. **Journal of Molecular Biology**. 103: 227-249.
- Whitcomb, J.M. and S.H. Hughes. 1992. Retroviral reverse transcription and integration: progress and problems. **Annual Review Cell Biology**. 8: 275-306.
- Wyatt, P.G., R.C. Bethell, N. Cammack, D. Charon, N. Dodic, B. Dumaitre, D.N. Evans, D.V.S. Green, P.L. Hopewell, D.C. Humber, R.B. Lamont, D.C. Orr, S.J. Plested, D.M. Ryan, S.L., Sollis, R. Storer and G.G. Weingarten. 1995. Benzophenone derivatives: A novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. **Journal of Medicinal Chemistry**. 38: 1657-1665.
- Young, S.D., S.F. Britcher, L.E. Tran, L.S. Payne, W.C. Lumma, T.A. Lyle, J.R. Huff, P.S. Anderson, D.B. Olsen, S.S. Carroll, D.J. Pettibone, J.A. O'Brien, R.G. Ball, S.K. Balani, J.H. Lin, I.W. Chen, W.A. Schleif, V.V. Sardana, W.J. Long, V.W. Byrnes and E.A. Emini. 1995. L-743,726 (DMP-226): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptases. **Antimicrobial Agents and Chemotherapy**. 39: 2602-2605.

